Tracheoesophageal fistula and esophageal perforation in a patient with advanced gastroesophageal junction tumor post ramucirumab treatment. A case report and literature review
<h3>Background</h3><p dir="ltr">Ramucirumab is an anti-angiogenic drug that received Food and Drug Administration (FDA)-approvals for treatments of many cancers. Gastrointestinal fistulas and perforations are recognized side effects of anti-angiogenic therapies, however,...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , |
| منشور في: |
2023
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| الملخص: | <h3>Background</h3><p dir="ltr">Ramucirumab is an anti-angiogenic drug that received Food and Drug Administration (FDA)-approvals for treatments of many cancers. Gastrointestinal fistulas and perforations are recognized side effects of anti-angiogenic therapies, however, there are very few reported cases of these conditions in patients managed with Ramucirumab. Here we report a case of a 46-year-old gentleman with a stage four gastroesophageal junction tumor, who developed multiple tracheoesophageal fistulas post ramucirumab containing regimen. To the best of our knowledge, this is the first case report that describes a serious uncommon complication of ramucirumab in a patient with a gastroesophageal junction tumor.</p><h2>Other Information</h2><p dir="ltr">Published in: Current Problems in Cancer: Case Reports<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.cpccr.2022.100214" target="_blank">https://dx.doi.org/10.1016/j.cpccr.2022.100214</a></p> |
|---|